

## **METHOCARBAMOL- methocarbamol tablet** **Preferred Pharmaceuticals, Inc**


-----  
**Methocarbamol Tablets, USP 500 mg**  
**Methocarbamol Tablets, USP 750 mg**

**Rx Only**

### **DESCRIPTION**

Methocarbamol Tablets, USP, 500 mg and 750 mg, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1, 2-propanediol 1-carbamate and has the empirical formula  $C_{11}H_{15}NO_5$ . Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and *n*-hexane.

Each tablet, for oral administration, contains either 500 mg or 750 mg of methocarbamol, USP. The inactive ingredients present are colloidal silicon dioxide, magnesium stearate, povidone, pregelatinized corn starch, purified water, sodium starch glycolate, and stearic acid.

### **CLINICAL PHARMACOLOGY**

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

### **Pharmacokinetics**

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in

the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

## **Special populations**

### *Elderly*

The mean ( $\pm$  SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [ $\pm$  SD] age, 69 [ $\pm$  4] years) was slightly prolonged compared to a younger (mean [ $\pm$  SD] age, 53.3 [ $\pm$  8.8] years), healthy population (1.5 [ $\pm$ 0.4] hours versus 1.1 [ $\pm$  0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

### *Renally impaired*

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean ( $\pm$  SD) elimination half-life in these two groups was similar: 1.2 ( $\pm$  0.6) versus 1.1 ( $\pm$  0.3) hours, respectively.

### *Hepatically impaired*

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean ( $\pm$  SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 ( $\pm$ 1.62) hours and 1.11 ( $\pm$  0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

## **INDICATIONS AND USAGE**

Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.

Methocarbamol does not directly relax tense skeletal muscles in man.

## **CONTRAINDICATIONS**

Methocarbamol is contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

## **WARNINGS**

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).

## **Use in Activities Requiring Mental Alertness**

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

## **PRECAUTIONS**

### **Information for Patients**

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

### **Drug Interactions**

See and PRECAUTIONS for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

### **Drug/Laboratory Test Interactions**

Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

### **Pregnancy**

#### *Teratogenic Effects – Pregnancy Category C*

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).

## **Nursing Mothers**

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.

## **Pediatric Use**

Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

## **ADVERSE REACTIONS**

Adverse reactions reported coincident with the administration of methocarbamol include:

*Body as a whole:* Anaphylactic reaction, angioneurotic edema, fever, headache

*Cardiovascular system:* Bradycardia, flushing, hypotension, syncope, thrombophlebitis

*Digestive system:* Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

*Hemic and lymphatic system:* Leukopenia

*Immune system:* Hypersensitivity reactions

*Nervous system:* Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

*Skin and special senses:* Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

## **OVERDOSAGE**

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

## **Treatment**

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

## **DOSAGE AND ADMINISTRATION**

Methocarbamol, 500 mg — Adults: Initial dosage: 3 tablets q.i.d.  
Maintenance dosage: 2 tablets q.i.d.

Methocarbamol, 750 mg — Adults: Initial dosage: 2 tablets q.i.d.  
Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

## **HOW SUPPLIED**

Methocarbamol Tablets, USP 500 mg — white, round, convex face, debossed “611” over bisect and “O” below bisect on one side and plain on the reverse side.  
Available in:

Bottles of 30, NDC number 68788-7973-3  
Bottles of 60, NDC number 68788-7973-6  
Bottles of 90, NDC number 68788-7973-9

Store at 20°- 25°C (68°- 77°F) [See USP Controlled Room Temperature].

Dispense in tight container.

For more information, call Oxford Pharmaceuticals, LLC at 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday – Friday

Manufactured by:

**OXFORD PHARMACEUTICALS**

Birmingham, AL 35211

8200004

Rev 12/20

R01

**Repackaged By: Preferred Pharmaceuticals Inc.**

## **PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

**NDC 68788-7973**

**METHOCARBAMOL  
TABLETS, USP  
500 mg**

**Rx only**

## **EACH TABLET CONTAINS:**

Methocarbamol, USP ... 500 mg

**DOSAGE:** See package insert for full prescribing information.

**DISPENSE** in a tight container

**STORE** at 20 to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured by:

**OXFORD  
PHARMACEUTICALS, LLC  
BIRMINGHAM, AL 35211  
Rev. 05/19 R00  
8000021**

**Repackaged By: Preferred Pharmaceuticals Inc.**

<p><b>Methocarbamol Tab. USP 500mg</b> Generic for Robaxin</p> <p>Each tablet contains: Methocarbamol, USP ... 500mg</p> <p><b>Pkg Size:</b> Exp Date: #####/####/ Lot#: Batch#:</p> <p>Ins: Mfg: Oxford Pharmaceuticals, LLC Prod#:</p> <p><b>Warning</b> Store at 20°- 25°C (68°- 77°F). See USP Controlled Room Temperature, RX Only. Keep this and all medication out of the reach of children. Tablet is round, white, scored and imprinted with 611 O.</p>		<p>CAUTION: Federal law PROHIBITS transfer of this drug to any person other than the patient for whom it was prescribed.</p>	<p>Methocarbamol Tab. USP 500mg Qty: Ins: Lot: Bat: Prod# (NDC):</p>	<p>Log</p>
<p>Directions English <b>May cause drowsiness. Do not drink alcohol while taking this medicine</b></p>		<p></p> <p>GTIN ##### SN ##### EXP #####</p>	<p>Methocarbamol Tab. USP 500mg Qty: Ins: Lot: Bat: Prod# (NDC):</p>	<p>Chart</p>
		<p><b>Instrucciones Espanol:</b> <b>Puede causar somnia. No tome bebidas alcoholicas mientras toma esta medicina. Toma ___ tableta(s) cada ___ horas.</b></p>	<p>Methocarbamol Tab. USP 500mg Qty: Ins: Insurance NDC: Lot: Bat:</p>	<p>Billing</p>
			<p>Methocarbamol Tab. USP 500mg Qty: Ins: Lot: Bat: Prod# (NDC):</p>	<p>Patient</p>

METHOCARBAMOL			
methocarbamol tablet			
Product Information			
<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:68788-7973(NDC:69584-611)
<b>Route of Administration</b>	ORAL		
Active Ingredient/Active Moiety			
<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>	
Methocarbamol (UNII: 125OD7737X) (Methocarbamol - UNII:125OD7737X)	Methocarbamol	500 mg	
Inactive Ingredients			
<b>Ingredient Name</b>	<b>Strength</b>		
Silicon Dioxide (UNII: ETJ7Z 6XBU4)			
Magnesium Stearate (UNII: 70097M6I30)			
Povidone K90 (UNII: RDH86HJV5Z)			

<b>Starch, Corn</b> (UNII: O8232NY3SJ)	
<b>Water</b> (UNII: 059QF0KO0R)	
<b>Sodium Starch Glycolate Type A Potato</b> (UNII: 5856J3G2A2)	
<b>Stearic Acid</b> (UNII: 4ELV7Z65AP)	

### Product Characteristics

<b>Color</b>	WHITE	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	13mm
<b>Flavor</b>		<b>Imprint Code</b>	611;0
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68788-7973-3	30 in 1 BOTTLE; Type 0: Not a Combination Product	07/28/2021	
2	NDC:68788-7973-6	60 in 1 BOTTLE; Type 0: Not a Combination Product	07/28/2021	
3	NDC:68788-7973-9	90 in 1 BOTTLE; Type 0: Not a Combination Product	07/28/2021	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040489	07/28/2021	

**Labeler** - Preferred Pharmaceuticals, Inc (791119022)

**Registrant** - Preferred Pharmaceuticals, Inc (791119022)

### Establishment

Name	Address	ID/FEI	Business Operations
Preferred Pharmaceuticals, Inc		791119022	REPACK(68788-7973)

Revised: 8/2025

Preferred Pharmaceuticals, Inc